Literature DB >> 15734768

Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.

Paul Sorajja1, Bernard J Gersh, Costantino Costantini, Michael G McLaughlin, Peter Zimetbaum, David A Cox, Eulogio Garcia, James E Tcheng, Roxana Mehran, Alexandra J Lansky, David E Kandzari, Cindy L Grines, Gregg W Stone.   

Abstract

AIMS: ST-segment recovery (SigmaSTR) and myocardial blush (MB) evaluate different elements of microcirculatory integrity after reperfusion therapy in acute myocardial infarction (AMI). We sought to determine whether the combination of SigmaSTR and MB after primary percutaneous coronary intervention (PCI) in AMI has greater prognostic utility than either measure alone. METHODS AND
RESULTS: The 30 days and 1 year clinical outcomes of 456 patients were assessed as a function of SigmaSTR and MB after primary PCI from the CADILLAC trial. SigmaSTR and MB were concordant (> or =70% SigmaSTR and MB grade 2/3 or <70% SigmaSTR and MB grade 0/1) in 60.1% of patients and discordant in 39.9% of patients. The greatest survival was observed among patients with complete SigmaSTR (> or =70%) and MB grade 2/3 in whom the cumulative rates of death at 30 days and 1 year were 0.6 and 1.2%, respectively. Poorest survival was observed among patients with incomplete SigmaSTR (<70%) and reduced MB (grade 0/1), in whom 30 days and 1 year rates of death were 8.3 and 10.1%, respectively. Intermediate outcomes were present in patients with discordant MB and SigmaSTR. By multivariable analysis, however, SigmaSTR was an independent correlate of survival at 30 days and 1 year (P=0.05 and 0.01, respectively), whereas MB was no longer predictive (P=0.38 and 0.72, respectively).
CONCLUSION: SigmaSTR and MB are not infrequently discordant after primary PCI. By univariate analysis, both measures of reperfusion success strongly correlate with survival and assessment of both yields incremental prognostic information beyond either measure alone. By multivariable analysis, however, SigmaSTR is the stronger prognostic variable.

Entities:  

Mesh:

Year:  2005        PMID: 15734768     DOI: 10.1093/eurheartj/ehi167

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  26 in total

Review 1.  Endothelial dysfunction over the course of coronary artery disease.

Authors:  Enrique Gutiérrez; Andreas J Flammer; Lilach O Lerman; Jaime Elízaga; Amir Lerman; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2013-09-07       Impact factor: 29.983

2.  The influence of coronary plaque morphology assessed by optical coherence tomography on final microvascular function after stenting in patients with ST-elevation myocardial infarction.

Authors:  Giovanni L De Maria; Niket Patel; Mathias Wolfrum; Gregor Fahrni; George Kassimis; Italo Porto; Sam Dawkins; Robin P Choudhury; John C Forfar; Bernard D Prendergast; Keith M Channon; Rajesh K Kharbanda; Hector M Garcia-Garcia; Adrian P Banning
Journal:  Coron Artery Dis       Date:  2017-05       Impact factor: 1.439

3.  ST-segment resolution prior to primary percutaneous coronary intervention is a poor indicator of coronary artery patency in patients with acute myocardial infarction.

Authors:  Niels J Verouden; Joost D Haeck; Karel T Koch; José P Henriques; Jan Baan; René J van der Schaaf; Marije M Vis; Ron J Peters; Arthur A Wilde; Jan J Piek; Jan G Tijssen; Robbert J de Winter
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

4.  The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Alaa Quisi; Gökhan Alıcı
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

5.  Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction.

Authors:  L De Luca; G Sardella; C J Davidson; G De Persio; M Beraldi; T Tommasone; M Mancone; B L Nguyen; L Agati; M Gheorghiade; F Fedele
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

6.  Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion.

Authors:  Giampaolo Niccoli; Andrea Celestini; Camilla Calvieri; Nicola Cosentino; Elena Falcioni; Roberto Carnevale; Cristina Nocella; Francesco Fracassi; Marco Roberto; Roberta P Antonazzo; Pasquale Pignatelli; Filippo Crea; Francesco Violi
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09-05

7.  No-reflow reversibility: a study based on serial assessment of multiple biomarkers.

Authors:  Giampaolo Niccoli; Francesco Fracassi; Nicola Cosentino; Elena Falcioni; Marco Roberto; Giuseppe De Luca; Antonio Maria Leone; Francesco Burzotta; Italo Porto; Carlo Trani; Anna Severino; Filippo Crea
Journal:  J Cardiovasc Transl Res       Date:  2013-09-06       Impact factor: 4.132

8.  Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study.

Authors:  Elena Guerra; Martin Hadamitzky; Gjin Ndrepepa; Corinna Bauer; Tareq Ibrahim; Ilka Ott; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-30       Impact factor: 2.357

9.  Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients.

Authors:  Nicolas Meneveau; Marie France Séronde; Vincent Descotes-Genon; Joanna Dutheil; Romain Chopard; Fiona Ecarnot; Florent Briand; Yvette Bernard; François Schiele; Jean-Pierre Bassand
Journal:  Clin Res Cardiol       Date:  2009-02-09       Impact factor: 5.460

Review 10.  Coronary microvascular dysfunction in the clinical setting: from mystery to reality.

Authors:  Joerg Herrmann; Juan Carlos Kaski; Amir Lerman
Journal:  Eur Heart J       Date:  2012-08-22       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.